المؤلفون: Fairhurst, K., Roberts, K., Fairbrother, P., Potter, S., Abbott, Nick, Achuthan, Raj, Ahmed, Goran, Ainsworth, Rachel, Arthur, Laura, Bains, Salena, Barber, Zoe, Batt, Jeremy, Bell, Ashleigh, Carter, Jane, Chambers, Alice, Conway, Anna, Courtney, Carol-Ann, Daltrey, Ian, Daoud, Raouf, Dash, Isabella, Dave, Rajiv, Dicks, Julia, Donigiewicz, Urszula, Fatayer, Hiba, Glassman, Daniel, Green, Nikki, Gutteridge, Eleanor, Hamad, Ahmed, Hargreaves, Anita, Harvey, James, Hassan Ali, Shaziya, Helme, Sophie, Henderson, Julia, Hignett, Susan, Hoar, Fiona, Horsnell, Jonathan, Hubbard, Thomas, Humphreys, Alex, Iqbal, Javeria, Johnson, Omotayo, Joshi, Meera, Kallaway, Charlotte, Karat, Isabella, Kim, Baek, Kleidi, Eleftheria, Kothari, Manish, Laban, Chrissie, Lambert, Kelly, Laws, Siobhan, Leeper, Alexander

المساهمون: National Institute for Health and Care Research

المصدر: Breast Cancer Research and Treatment ; volume 203, issue 2, page 187-196 ; ISSN 0167-6806 1573-7217

مصطلحات موضوعية: Cancer Research, Oncology

الوصف: Purpose Up to 40% of the 56,000 women diagnosed with breast cancer each year in the UK undergo mastectomy. Seroma formation following surgery is common, may delay wound healing, and be uncomfortable or delay the start of adjuvant treatment. Multiple strategies to reduce seroma formation include surgical drains, flap fixation and external compression exist but evidence to support best practice is lacking. We aimed to survey UK breast surgeons to determine current practice to inform the feasibility of undertaking a future trial. Methods An online survey was developed and circulated to UK breast surgeons via professional and trainee associations and social media to explore current attitudes to drain use and management of post-operative seroma. Simple descriptive statistics were used to summarise the results. Results The majority of surgeons (82/97, 85%) reported using drains either routinely (38, 39%) or in certain circumstances (44, 45%). Other methods for reducing seroma such as flap fixation were less commonly used. Wide variation was reported in the assessment and management of post-operative seromas. Over half (47/91, 52%) of respondents felt there was some uncertainty about drain use after mastectomy and axillary surgery and two-thirds (59/91, 65%) felt that a trial evaluating the use of drains vs no drains after simple breast cancer surgery was needed. Conclusions There is a need for a large-scale UK-based RCT to determine if, when and in whom drains are necessary following mastectomy and axillary surgery. This work will inform the design and conduct of a future trial.

الإتاحة: https://doi.org/10.1007/s10549-023-07042-7Test

المؤلفون: Abraham, Jean E., Pinilla, Karen, Dayimu, Alimu, Grybowicz, Louise, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M., Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N., Worley, Joanna R., Chhabra, Anita, Qian, Wendi, Vallier, Anne-Laure, Hardy, Richard M., Chan, Steve, Hickish, Tamas, Tripathi, Devashish, Venkitaraman, Ramachandran, Persic, Mojca, Aslam, Shahzeena, Glassman, Daniel, Raj, Sanjay, Borley, Annabel, Braybrooke, Jeremy P., Sutherland, Stephanie, Staples, Emma, Scott, Lucy C., Davies, Mark, Palmer, Cheryl A., Moody, Margaret, Churn, Mark J., Newby, Jacqueline C., Mukesh, Mukesh B., Chakrabarti, Amitabha, Roylance, Rebecca R., Schouten, Philip C., Levitt, Nicola C., McAdam, Karen, Armstrong, Anne C., Copson, Ellen R., McMurtry, Emma, Tischkowitz, Marc, Provenzano, Elena, Earl, Helena M.

المصدر: Nature; May 2024, Vol. 629 Issue: 8014 p1142-1148, 7p

مستخلص: PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1and BRCA2wild type3. Here we report the results of the trial. Patients (n= 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P= 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P> 0.9), respectively; OS was 90% and 87.2% (log-rank P= 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P< 0.001), and OS was 96% and 83% (log-rank P< 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1and BRCA2wild type. ClinicalTrials.gov ID: NCT03150576.

المؤلفون: Abraham, Jean E, Pinilla, Karen, Dayimu, Alimu, Grybowicz, Louise, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M, Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N, Worley, Joanna R, Chhabra, Anita, Qian, Wendi, Vallier, Anne-Laure, Hardy, Richard M, Chan, Steve, Hickish, Tamas, Tripathi, Devashish, Venkitaraman, Ramachandran, Persic, Mojca, Aslam, Shahzeena, Glassman, Daniel, Raj, Sanjay, Borley, Annabel, Braybrooke, Jeremy P, Sutherland, Stephanie, Staples, Emma, Scott, Lucy C, Davies, Mark, Palmer, Cheryl A, Moody, Margaret, Churn, Mark J, Newby, Jacqueline C, Mukesh, Mukesh B, Chakrabarti, Amitabha, Roylance, Rebecca R, Schouten, Philip C, Levitt, Nicola C, McAdam, Karen, Armstrong, Anne C, Copson, Ellen R, McMurtry, Emma, Tischkowitz, Marc, Provenzano, Elena, Earl, Helena M

مصطلحات موضوعية: Adult, Aged, Female, Humans, Middle Aged, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Genes, BRCA1, BRCA2, Neoadjuvant Therapy, Paclitaxel, Pathologic Complete Response, Phthalazines, Piperazines, Progression-Free Survival, Prospective Studies, Survival Analysis, Time Factors, Triple Negative Breast Neoplasms, Adolescent, Young Adult

الوصف: Acknowledgements: We thank the patients, and the families and friends who supported them, for participating in this trial; our ethics committee, our independent data and safety monitoring committee and the trial management group for their advisory roles; the PARTNER trial consortium members, past and present (Supplementary Information); and I. Cizaite for preparing and proofreading the manuscript. This trial was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, and financed by a project grant from AstraZeneca, who also supplied olaparib. Cancer Research UK provided peer review and endorsement for the study and financed the sample collections for the translational studies, which will be reported separately. We also acknowledge the National Institute for Health and Care Research Cambridge Biomedical Research Centre and the Cancer Research UK Cambridge Centre for their financial support for staff and infrastructure costs. The funders had no role in data collection or analysis. Once the trial group had interpreted the data, the results were then shared with the AstraZeneca scientists. In addition, we thank the Cancer Molecular Diagnostics Laboratory and The Precision Breast Cancer Institute Team for their support for sample collection; Cambridge Tissue Bank (NIHR203312) for sample assessment and diagnostics; Cambridge Clinical Trials Centre – Cancer Theme for their core staff support; the clinical trials support staff at all participating sites; and Addenbrookes Charitable Trust for financing the post of the chief investigator (2015–2018). We acknowledge Cancer Research UK (CRUKE/14/048) and AstraZeneca (1994-A093777). ; PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib ...

وصف الملف: application/zip; text/xml; application/pdf

العلاقة: https://www.repository.cam.ac.uk/handle/1810/369017Test

الإتاحة: https://www.repository.cam.ac.uk/handle/1810/369017Test

المؤلفون: Hlina, Benjamin L.¹ (AUTHOR) benjamin.hlina@gmail.com, Glassman, Daniel M.¹ (AUTHOR), Lédée, Elodie J. I.¹ (AUTHOR), Nowell, Liane B.² (AUTHOR), Claussen, Julie E.³ (AUTHOR), Philipp, David P.³ (AUTHOR), Marsden, J. Ellen⁴ (AUTHOR), Power, Michael⁵ (AUTHOR), Cooke, Steven J.¹ (AUTHOR)

المصدر: Aquatic Sciences. Apr2024, Vol. 86 Issue 2, p1-14. 14p.

مستخلص: Bioenergetics models for fishes are useful for understanding ecological processes (e.g., survivorship, growth, and reproduction) and can also inform fisheries management. Yet, current bioenergetics models are unable to ascertain direct energetic costs associated with standard and active metabolism for wild, free-swimming fishes. The use of telemetry with accelerometer sensors, calibrated in the laboratory using swim tunnel respirometers, have made it possible to estimate field metabolic activity in wild fish. Our objectives were to determine seasonal thermal habitat use and habitat-dependent metabolic costs associated with standard, active, and maximum metabolism in a ~1400 ha multibasin lake in Québec, Canada. We implanted 47 wild, free-swimming Lake Trout (Salvelinus namaycush) with either acoustic transmitters equipped with temperature and depth sensors or an acceleration sensor. Three sets of water temperature loggers (one set for each basin) were deployed at 2, 4, 6, 10, and 18 or 20 m to measure seasonally available thermal habitat. Thermal profiles of lake water temperature varied among basins with the thermocline being ~5 m in the smallest basin (north basin) and ~7.5 m in the largest basin (east basin). Thermal habitat used by Lake Trout varied seasonally, coupled with seasonal and basin differences in standard and maximum metabolism. Daily active metabolism loosely followed seasonal changes in thermal habitat use but was largely unaffected by differences in thermal habitat use among capture basins. The theoretical scope-for-activity followed seasonal trends and was estimated to range between 47% and 74% of theoretical aerobic scope. Our observations suggest that available thermal habitats influence Lake Trout thermal habitat use, and thus metabolic costs associated with swimming. These changes in thermal habitats could have metabolic consequences for individuals in a population, resulting in altered fitness metrics (i.e., survival, growth, and/or reproduction). Reductions in the volume and availability of optimal thermal habitats for Lake Trout are likely to occur under climate change scenarios. Our study indicates that the species can adjust metabolic costs throughout the year even when thermal habitats appear to be limiting, which may inform future evidence-based management decisions. [ABSTRACT FROM AUTHOR]

المؤلفون: GLASSMAN, DANIEL

المصدر: Point of View Magazine; Fall2023, Issue 119, p44-47, 4p, 5 Color Photographs, 1 Black and White Photograph

المؤلفون: Yiasemidou, Marina, Glassman, Daniel, Jayne, David, Miskovic, Danilo

المساهمون: Leeds Teaching Hospitals Charitable Foundation

المصدر: Computer Assisted Surgery ; volume 23, issue 1, page 57-68 ; ISSN 2469-9322

الإتاحة: https://doi.org/10.1080/24699322.2018.1495266Test

المؤلفون: Yiasemidou, Marina, Roberts, David, Glassman, Daniel, Tomlinson, James, Biyani, Shekhar, Miskovic, Danilo

المصدر: World Journal of Surgery ; volume 41, issue 5, page 1201-1207 ; ISSN 0364-2313 1432-2323

الوصف: Background Changes in UK legislation allow for surgical procedures to be performed on cadavers. The aim of this study was to assess Thiel cadavers as high‐fidelity simulators and to examine their suitability for surgical training. Methods Surgeons from various specialties were invited to attend a 1 day dissection workshop using Thiel cadavers. The surgeons completed a baseline questionnaire on cadaveric simulation. At the end of the workshop, they completed a similar questionnaire based on their experience with Thiel cadavers. Comparing the answers in the pre‐ and post‐workshop questionnaires assessed whether using Thiel cadavers had changed the surgeons’ opinions of cadaveric simulation. Results According to the 27 participants, simulation is important for surgical training and a full‐procedure model is beneficial for all levels of training. Currently, there is dissatisfaction with existing models and a need for high‐fidelity alternatives. After the workshop, surgeons concluded that Thiel cadavers are suitable for surgical simulation ( p = 0.015). Thiel were found to be realistic ( p < 0.001) to have reduced odour ( p = 0.002) and be more cost‐effective ( p = 0.003). Ethical constraints were considered to be small. Conclusion Thiel cadavers are suitable for training in most surgical specialties.

الإتاحة: https://doi.org/10.1007/s00268-016-3868-4Test

المؤلفون: Yiasemidou, Marina, Galli, Raffaele, Glassman, Daniel, Tang, Matthew, Aziz, Rahoz, Jayne, David, Miskovic, Danilo

المساهمون: Leeds Teaching Hospitals Charitable Foundation

المصدر: Surgical Endoscopy ; volume 32, issue 3, page 1165-1173 ; ISSN 0930-2794 1432-2218

مصطلحات موضوعية: Surgery

الإتاحة: https://doi.org/10.1007/s00464-017-5788-2Test

المؤلفون: Yiasemidou, Marina, Glassman, Daniel, Mushtaq, Faisal, Athanasiou, Christos, Williams, Mark-Mon, Jayne, David, Miskovic, Danilo

المصدر: Surgical Endoscopy ; volume 31, issue 10, page 4111-4117 ; ISSN 0930-2794 1432-2218

مصطلحات موضوعية: Surgery

الإتاحة: https://doi.org/10.1007/s00464-017-5459-3Test

المؤلفون: Glassman, Daniel J.

المصدر: Florida Law Review

مصطلحات موضوعية: Law

وصف الملف: application/pdf

العلاقة: https://scholarship.law.ufl.edu/flr/vol58/iss3/4Test; https://scholarship.law.ufl.edu/cgi/viewcontent.cgi?article=1907&context=flrTest

الإتاحة: https://scholarship.law.ufl.edu/flr/vol58/iss3/4Test
https://scholarship.law.ufl.edu/cgi/viewcontent.cgi?article=1907&context=flrTest